Latest Insider Transactions at Jounce Therapeutics, Inc. (JNCE)
This section provides a real-time view of insider transactions for Jounce Therapeutics, Inc. (JNCE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jounce Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jounce Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,450,000
-15.76%
|
$15,950,000
$11.75 P/Share
|
|
Feb 16
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.94%
|
$2,200
$11.78 P/Share
|
|
Feb 03
2021
|
Richard /Ca/ Murray Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+3.26%
|
-
|
|
Feb 01
2021
|
Hugh M Cole Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+26.54%
|
-
|
|
Feb 01
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+25.38%
|
-
|
|
Feb 01
2021
|
Richard /Ca/ Murray Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+25.83%
|
-
|
|
Feb 01
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+19.21%
|
-
|
|
Jan 22
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,000
-27.61%
|
$198,000
$11.95 P/Share
|
|
Jan 22
2021
|
Hugh M Cole Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.4%
|
$50,000
$5.48 P/Share
|
|
Jan 21
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
33,518
-19.28%
|
$402,216
$12.06 P/Share
|
|
Jan 21
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
33,518
+16.16%
|
$0
$0.48 P/Share
|
|
Jan 21
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,799
-8.09%
|
$45,588
$12.0 P/Share
|
|
Jan 21
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,799
+7.48%
|
$7,598
$2.36 P/Share
|
|
Jan 21
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.9%
|
$2,200
$11.11 P/Share
|
|
Jan 20
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
26,201
-21.08%
|
$288,211
$11.03 P/Share
|
|
Jan 20
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,501
+6.43%
|
$13,501
$1.19 P/Share
|
|
Jan 20
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
1,500
-12.49%
|
$18,000
$12.0 P/Share
|
|
Jan 20
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,500
-8.35%
|
$78,000
$12.01 P/Share
|
|
Jan 20
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+7.71%
|
$26,000
$4.02 P/Share
|
|
Jan 20
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
16,482
-10.51%
|
$197,784
$12.04 P/Share
|
|
Jan 20
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,482
+9.51%
|
$0
$0.48 P/Share
|
|
Jan 19
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
40,000
-22.18%
|
$360,000
$9.59 P/Share
|
|
Jan 19
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.15%
|
$0
$0.48 P/Share
|
|
Jan 15
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
30,000
-17.61%
|
$240,000
$8.54 P/Share
|
|
Jan 15
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.97%
|
$0
$0.48 P/Share
|
|
Jan 08
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,340
-5.71%
|
$23,380
$7.0 P/Share
|
|
Jan 08
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,130
-5.3%
|
$21,910
$7.0 P/Share
|
|
Jan 08
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
11,816
-7.76%
|
$82,712
$7.0 P/Share
|
|
Jan 08
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,846
-3.84%
|
$19,922
$7.0 P/Share
|
|
Jan 07
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,879
-4.69%
|
$17,274
$6.76 P/Share
|
|
Jan 07
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
2,697
-4.37%
|
$16,182
$6.76 P/Share
|
|
Jan 07
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
10,183
-6.27%
|
$61,098
$6.76 P/Share
|
|
Jan 07
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,452
-3.2%
|
$14,712
$6.76 P/Share
|
|
Nov 19
2020
|
Cary Pfeffer Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Nov 19
2020
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
15,000
-0.16%
|
$105,000
$7.0 P/Share
|
|
Nov 17
2020
|
Cary Pfeffer Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Nov 17
2020
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
15,000
-0.16%
|
$105,000
$7.25 P/Share
|
|
Nov 11
2020
|
Cary Pfeffer Director |
SELL
Other acquisition or disposition
|
Indirect |
0
|
-
|
|
Nov 11
2020
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-9.77%
|
-
|